LifeStance Health Group (NASDAQ:LFST) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of LifeStance Health Group (NASDAQ:LFST) from a hold rating to a buy rating in a research report report published on Sunday morning.

Several other equities analysts also recently issued reports on the stock. BTIG Research boosted their price target on shares of LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, February 2nd. BMO Capital Markets initiated coverage on LifeStance Health Group in a report on Thursday, November 13th. They set an “outperform” rating and a $8.00 target price on the stock. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. UBS Group upped their price target on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Barclays initiated coverage on LifeStance Health Group in a report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

LifeStance Health Group Trading Up 4.6%

Shares of NASDAQ LFST opened at $6.84 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $2.66 billion, a P/E ratio of -228.00 and a beta of 1.12. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.30. The stock’s 50 day moving average price is $7.01 and its two-hundred day moving average price is $5.92.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The firm had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm’s revenue was up 16.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.02) earnings per share. On average, analysts anticipate that LifeStance Health Group will post -0.18 earnings per share for the current fiscal year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the transaction, the insider owned 315,610 shares in the company, valued at approximately $2,177,709. This represents a 13.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Bessler sold 119,942 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the sale, the director owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. The trade was a 8.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 327,326 shares of company stock valued at $2,259,317. Corporate insiders own 6.60% of the company’s stock.

Institutional Trading of LifeStance Health Group

Institutional investors have recently bought and sold shares of the company. Royal Bank of Canada increased its position in LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after purchasing an additional 27,244 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of LifeStance Health Group by 223.0% in the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock valued at $343,000 after buying an additional 35,554 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in LifeStance Health Group by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after acquiring an additional 4,169 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in LifeStance Health Group by 1.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after acquiring an additional 11,331 shares in the last quarter. Finally, Blair William & Co. IL acquired a new stake in LifeStance Health Group in the second quarter valued at approximately $70,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.